Navigation Links
Link between treating osteoporosis with bisphosphonates and incidence of bone necrosis examined
Date:2/16/2008

BOSTON, Feb. 16, 2008 According to the National Osteoporosis Foundation, osteoporosis affects some 25 million Americans annually, 80 percent of them women. Because the disease causes a thinning of the bone, it can lead to hip fractures, spinal fractures and a whole host of debilitating and sometimes deadly complications.

Bisphosphonates (BFs), such as popularly prescribed Fosamax (alendronate sodium), are a class of drugs that act to prevent bone fractures in patients with osteoporosis as well as prevent bone metastases and related skeletal problems in patients with cancer, including multiple myeloma, metastatic breast and prostate cancers.

In 2003, the first reports emerged of a new disease, called osteonecrosis of the jaw (ONJ), found in patients who were using BFs. ONJ is characterized by bone necrosis and prolonged exposure of the jaw bone to the oral cavity. It has frequently occurred in older people who have had an oral surgical procedure or trauma to the jaw bones.

The incidence of ONJ is the subject of recent research by John T. Grbic, DDS, MMSc, of Columbia Universitys College of Dental Medicine. Since the identification of ONJ as a disease, Dr. Grbic has made a continuous effort to identify the incidence, risk factors, and pathogenesis of this new disease entity.

On Saturday, Feb. 16, at 10 a.m., in Hynes Convention Center Rm. 112, Dr. Grbic will be part of an American Academy for the Advancement of Science (AAAS) press conference that focuses on the pharmacology of BFs, with data supporting the use of BFs therapy in both oncology and non-oncology patients. He also will give an overview of the potential pathogenic mechanisms involved in the development of ONJ. He will later discuss these findings at an AAAS scientific symposia session from 1:45 p.m. 3:15 p.m. in Rm. 206.

Earlier reports of ONJ have had a significant effect on the use of BFs to treat patients with osteoporosis and cancer. Dr. Grbic and his team have found in a study of more than 7,000 patients, that the use of BFs to treat osteoporosis has little or no effect on the incidence of osteonecrosis. However, when the disease presents itself in any patient is poses a significant treatment challenge for clinicians. Dr. Grbic will discuss these concerns at Saturdays press conference.

About Dr. John Grbic: Dr. Grbic is professor and director of the Division of Oral Biology and the Center for Clinical Research in Dentistry. Dr. Grbic received his dental degree from the Fairleigh Dickinson University School of Dentistry and obtained his residency training in periodontology from the Harvard School of Dental Medicine. Dr. Grbic also holds a Master of Medical Science degree in Oral Biology from Harvard University. Dr. Grbics special expertise includes periodontics (surgical and non-surgical), and implantology. Dr. Grbics paper Women with Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial, was the January 2008 cover story of the Journal of the American Dental Association.


'/>"/>

Contact: Susan Craig
sc2756@columbia.edu
212-203-8599
Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. Comparison of obstetric outcomes between on-call and patients own obstetricians
2. Mailman School of Public Health study examines link between racial discrimination and substance use
3. New link between estrogen and breast cancer
4. Link Uncovered Between Benign Prostatic Hyperplasia and NSAIDs, Says Harvard Mens Health Watch
5. Link Between Chronic Pain and Insomnia Uncovered at PAINWeek 2007
6. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
7. Researchers discover correlation between GERD and obesity in females
8. NIH awards $10.8M to Columbia to study connection between diabetes and heart disease
9. Researchers Pinpoint Link Between Caloric Restriction and Longevity
10. Link Between Air Pollution, Stroke Gets Clearer
11. No Link Between Anti-Nausea Drug, Heart Trouble
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... An in-depth computational ... the University of Pittsburgh points to eight genes that may explain why susceptibility to ... to the results of a study published today in the journal npj Schizophrenia. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of McKinney ... Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. ... to Highway 121. , As the practice has grown, the need for more space ...
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top five ... art competition. Selected from 15 submissions from around the nation, the top five finalists ... iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the competition ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, the celebrated ... Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, on Facebook. ... from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch of ...
(Date:2/23/2017)... ... 23, 2017 , ... Rare Disease Report®, which is the ... Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on ... weekly e-newsletter and quarterly publication, will be conducting interviews with patients and advocates ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Feb. 24, 2017 Research and Markets has ... & Trends - Industry Forecast to 2025" report to their ... The ... of around 23.8% over the next decade to reach approximately $330.5 ... estimates and forecasts for all the given segments on global as ...
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research and ... Analysis and Strategies - 2016" report to their offering. ... The latest research Dry eye Drugs ... in the global Dry eye market. The research answers the following ... for Dry eye and their clinical attributes? How are they positioned in ...
(Date:2/24/2017)... 24, 2017 Juan Monteverde , founder ... , a boutique securities firm headquartered at the Empire ... , announces that a class action lawsuit has been ...  against Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the ... July 23, 2015 and December 30, 2016, inclusive (the ...
Breaking Medicine Technology: